
1. Rev Pneumol Clin. 2015 Feb;71(1):20-6. doi: 10.1016/j.pneumo.2014.11.002. Epub
2015 Feb 11.

[Clinical, microbiological and evolutionary profile of patients experiencing
failures and relapses of tuberculosis in Ivory Coast].

[Article in French]

Kouamé-N'Takpé N(1), Horo K(2), Koné A(2), N'guessan KR(3), Touré K(4), Kouadio
C(2), Assi D(4), Coulibaly I(5), Kouakou A(6).

Author information: 
(1)Centre antituberculeux, Yopougon, Côte d'Ivoire. Electronic address:
raissantakpe@yahoo.fr.
(2)Service de pneumologie, CHU de Cocody, Abidjan, Côte d'Ivoire.
(3)Unité de mycobactérie, Institut Pasteur, Abidjan, Côte d'Ivoire.
(4)Centre antituberculeux, Adjamé, Côte d'Ivoire.
(5)Centre antituberculeux, Yopougon, Côte d'Ivoire.
(6)Programme national de lutte contre la tuberculose, Abidjan, Côte d'Ivoire.

INTRODUCTION: Multidrug-resistant tuberculosis (MDR-TB) is a major obsession for 
TB control. The main risk factor for MDR-TB remains a history of TB treatment
especially bad conduct. The objective of this study is to describe the profile of
patients in situations of failure and relapse of tuberculosis.
METHODS: We performed a retrospective survey of the analysis of records of
patients starting TB retreatment for failure or relapse of tuberculosis. We used 
193 cases with results of culture-sensitivity.
RESULTS: The proportion of failure is 59/193 (30.6 %) and cases of relapse are
134/193 (69.4 %). The proportion of married life is 23.4 % (11/47) in chess
against 41.5 % (51/123) in relapse of TB [P=0.021, OR=0.431 (0.201 to 0.927)].
Patients failing therapy have more chest pain [5.8 % (3/52) versus 0 % (0/126)
with P=0.024]. The proportion of MDR-TB was 61.4 (38/59) in case of failure
against 41 % (55/134) in case of relapse [P=0.002, OR=2.599 (1.378 to 4.902)].
The evolution is the same whatever the indication of reprocessing.
CONCLUSION: The proportion of MDR-TB is very important in case of reprocessing
failure and relapse of tuberculosis.

Copyright © 2014 Elsevier Masson SAS. All rights reserved.

DOI: 10.1016/j.pneumo.2014.11.002 
PMID: 25681315  [Indexed for MEDLINE]

